Literature DB >> 17555371

Effects of anticoagulant strategies on activation of inflammation and coagulation.

Clemens Feistritzer1, Christian J Wiedermann.   

Abstract

Acute inflammatory events, such as those that occur in sepsis, lead to dysregulation of the coagulation cascade. The hemostatic imbalance in sepsis, characterized by the excessive activation of procoagulant pathways and the impairment of anticoagulant activity, leads to disseminated intravascular coagulation and results in microvascular thrombosis, tissue hypoperfusion and, ultimately, multiple organ failure and death. Furthermore, natural anti-inflammatory mechanisms of the endogenous anticoagulants are diminished by the impaired coagulation. Supportive strategies aiming at inhibiting activation of coagulation and inflammation by treatment with exogenous anticoagulants have been found to be beneficial in experimental and initial clinical studies. This review summarizes the available experimental and clinical data regarding the interaction between coagulation and inflammation, focusing on the two anticoagulants which are in clinical use, antithrombin and activated protein C. Identification of the different biological mechanisms of the two endogenous anticoagulants might help to determine target patient populations as well as to develop new anticoagulant analogs that differ in there respective effects in coagulation and inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555371     DOI: 10.1517/14712598.7.6.855

Source DB:  PubMed          Journal:  Expert Opin Biol Ther        ISSN: 1471-2598            Impact factor:   4.388


  21 in total

1.  Proteomic analysis of the nuclear phosphorylated proteins in dairy cow mammary epithelial cells treated with estrogen.

Authors:  Jian-Guo Huang; Xue-Jun Gao; Qing-Zhang Li; Li-Min Lu; Rong Liu; Chao-Chao Luo; Jia-Li Wang; Qiao Bin; Xin Jin
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-07-18       Impact factor: 2.416

Review 2.  The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients.

Authors:  Karen M Hook; Charles S Abrams
Journal:  Clin Transl Sci       Date:  2011-12-07       Impact factor: 4.689

3.  Fluid resuscitation targeting sepsis-induced cardiovascular dysfunction: severity of disease as effect modifier.

Authors:  Christian J Wiedermann; Stefan Dunzendorfer
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 4.  [Adjuvant treatment of sepsis: what is known?].

Authors:  C J Wiedermann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-10-22       Impact factor: 0.840

Review 5.  Novel pharmacologic approaches to the management of sepsis: targeting the host inflammatory response.

Authors:  Derek S Wheeler; Basilia Zingarelli; William J Wheeler; Hector R Wong
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2009-06

6.  Low molecular weight heparin prevents CLP-induced acute lung injury in rats by anti-inflammatory coagulation.

Authors:  Xiao Lu; Liang Zhao; Yong-Hua Xu
Journal:  Bosn J Basic Med Sci       Date:  2013-02       Impact factor: 3.363

7.  AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis.

Authors:  Feng Xu; Mary Lou Previti; Marvin T Nieman; Judianne Davis; Alvin H Schmaier; William E Van Nostrand
Journal:  J Neurosci       Date:  2009-04-29       Impact factor: 6.167

8.  Contribution of protein Z and protein Z-dependent protease inhibitor in generalized Shwartzman reaction.

Authors:  Antje Butschkau; Philipp Nagel; Eberhard Grambow; Dietmar Zechner; George J Broze; Brigitte Vollmar
Journal:  Crit Care Med       Date:  2013-12       Impact factor: 7.598

9.  Multi-organ failure in adult onset Still's disease: a septic disguise.

Authors:  Paul R J Ames; Emily Walker; Darren Aw; David Marshall; Francois de Villiers; Manfred Staber
Journal:  Clin Rheumatol       Date:  2008-10-07       Impact factor: 2.980

10.  In vivo anti-HIV activity of the heparin-activated serine protease inhibitor antithrombin III encapsulated in lymph-targeting immunoliposomes.

Authors:  Mohammed Asmal; James B Whitney; Corinne Luedemann; Angela Carville; Robert Steen; Norman L Letvin; Ralf Geiben-Lynn
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.